Hosted on MSN
Altimmune outlines PERFORMA Phase III MASH start in 2H 2026 and cash runway to 2029 52-week readout
"In April, we completed an oversubscribed public offering resulting in $225 million in gross proceeds" and "the proceeds from the April offering, along with our existing funds, resulted in a cash ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results